How can cancer drug prices better match their benefits? Germany offers a cost-saving model

10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...

Read more →

Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany

7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...

Read more →

Network meta-analyses: no compensation for weak evidence

7 July 2020 - BMJ publication headed by IQWiG: relevant controlled studies and individual patient data are necessary for informative ...

Read more →

Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority

1 July 2020 - Informative comparative data are missing / resistance situation not sufficiently considered in approval studies. ...

Read more →

The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany

15 June 2020 - Payers are increasingly calling for the value of new drugs to be measured explicitly.  ...

Read more →

Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2 million euros

24 June 2020 - Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal ...

Read more →

Romosozumab in osteoporosis: considerable added benefit for women after menopause

15 June 2020 - Fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high ...

Read more →

Lower prices and greater patient access — lessons from Germany’s drug purchasing structure

3 June 2020 - The German system for determining drug prices features collective negotiations on the part of competing health plans.  ...

Read more →

Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women

2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages ...

Read more →

Belimumab in active systemic lupus erythematosus: additional benefit for children and adolescents

14 May 2020 - Addendum with a new summary; subsequent information enables the benefits to be assessed. ...

Read more →

Bayer donates 8 million chloroquine tablets to the German Federal Government

14 April 2020 - Additional donations of chloroquine sent to governments in numerous other countries. ...

Read more →

Determinants of orphan drug prices in Germany

21 March 2020 - Legislation introduced in 2011 in Germany has instituted an early benefit assessment of newly licensed pharmaceuticals with ...

Read more →

Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs

24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...

Read more →

Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children

15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...

Read more →

Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit

15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...

Read more →